Premium
BROMOCRIPTINE IN THE TREATMENT OF ADVANCED PARKINSONISM
Author(s) -
Kristensen Ole,
Hansen Erik
Publication year - 1977
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1977.tb01434.x
Subject(s) - bromocriptine , levodopa , dyskinesia , placebo , parkinsonism , dopaminergic , parkinson's disease , medicine , anesthesia , dopamine agonist , psychology , disease , dopamine , prolactin , pathology , hormone , alternative medicine
The dopaminergic agonist bromocriptine in doses of 2.5–40 mg was compared with placebo in a double‐blind cross‐over study (12 + 12 weeks) in 11 Parkinson patients in whom bothering dgskinesia occurring after prolonged levodopa treatment limited in the levodopa dose to a level, where Parkinson symptoms still were present to an unsatisfactory degree. On the basis of changes in rating scales and the patients' preference, bromocriptine was significantly superior to placebo. Dgskinesia, occurring during bromocriptine treatment in 9 of 11 patients, disappeared within the period of study in 6 patients after dose reduction without changes in Parkinson disability scores to placebo level. Bromocriptine seem to be of value in cases where the balance between minimal dgskinesia and Parkinson symptoms is impossible to obtain with levodopa treatment alone.